Psyros Diagnostics has signed an agreement to be acquired by the Swedish company, Prolight Diagnostics AB. Psyros’s ground-breaking Point-of-Care (POC) technology enables the measurement of disease-indicating molecules in extremely low concentrations–in ten minutes or less.
21st January 2022
New figures from Health Education England (HEE) show that the pharmacist vacancy rate in community pharmacies across England has doubled to 8% between 2017 and 2021.
21st January 2022
The drug received conditional marketing authorisation in the UK from the MHRA in November
20th January 2022
Antibodies generated from only two vaccine doses offer less protection against the Omicron variant
20th January 2022
NICE also aims to make strides in digital, genomic and antimicrobial technologies
19th January 2022
Imfinzi has shown improvements in the overall survival of patients with biliary tract cancer
19th January 2022
The NHS launches world-first study investigating genetic testing for common diseases
18th January 2022
Cancer Research UK announces clinical trial for most common type of lung cancer
18th January 2022
Clinical stage outfit, Destiny Pharma, provides a positive summary of the year ahead
17th January 2022
If we have learnt anything from the last two years, it’s that virus protection is not to be sniffed at
17th January 2022
Vir Biotech has launched a new antibody research initiative, expanding its partnership with the Bill & Melinda Gates Foundation
14th January 2022
Djokovic drama causes a racket: so how would the UK respond?
14th January 2022
AstraZeneca (AZ) has reported preliminary data from a trial it conducted on its COVID-19 booster shot, Vaxzevria.
13th January 2022
Despite diagnosis and treatment options improving for the rare kidney condition, further action is urgently required.
13th January 2022
Under current guidelines, individuals that test positive for COVID-19 may be able to leave self-isolation after 7 days if certain conditions are met.
12th January 2022
